Medicine
Fyremadel 250 mcg/0.5 mL injection
Fyremadel 250 mcg/0.5 mL injection is a prescription medicine containing Ganirelix for subcutaneous use, marketed by Ferring Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C…
Key facts
- Active ingredient (INN)
- Ganirelix
- Brand
- Fyremadel
- Strength
- 250 mcg/0.5 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 blister pack of 0.5 mL
- Marketing authorisation holder
- Ferring Pharmaceuticals
- Manufacturer
- Ferring Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (59° and 86°F). Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01CC01 Ganirelix
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 February 2022
- Identifiers
- RxCUI 855200, 2587594DailyMed set ID 5f0908b5-3551-47fd-95f7-3669b0dff7f1NDC 55566-1010Application ANDA204246
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 1 syringe in 1 blister pack / .5 mL in 1 syringe | 55566-1010-1 | Ferring Pharmaceuticals | 28 February 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ganirelix 250 mcg/0.5 mL injection.
Other strengths and forms of Ganirelix
Clinical summary
Ganirelix is a gonadotropin releasing hormone receptor antagonist indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. It is available as injection for subcutaneous use. MedsAcross supplies Ganirelix for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GanirelixFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ganirelix Acetate prescribing information (Organon) · U.S. National Library of Medicine, DailyMed
- Orgalutran: European public assessment report (EPAR) · European Medicines Agency
- Ganirelix Gedeon Richter: European public assessment report (EPAR) · European Medicines Agency
Need Fyremadel 250 mcg/0.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.